The monokine, cachectin/tumor necrosis factor (TNF) differs from interleukin 1 (IL-1) in primary structure and in recognition by a distinct cellular receptor. It does, however, encode effector functions that are similar to those of IL-1 and characteristic of the host response to inflammation or tissue injury. Accordingly, we examined the possibility that recombinant-generated human TNF regulates hepatic acute-phase gene expression. In picomolar concentrations, TNF mediated reversible, dose-and time-dependent increases in biosynthesis of complement proteins factor B and C3, a, antichymotrypsin, and decreases in biosynthesis of albumin and transferrin in human hepatoma cell lines (Hep G2, Hep 3B). Biosynthesis of complement proteins C2 and C4, and a, proteinase inhibitor were not affected by TNF. TNF also increased factor B gene expression, but had no effect on C2 gene expression, in murine fibroblasts transfected with cosmid DNA bearing the human C2 and factor B genes. The effect of TNF on acute-phase protein expression (C3, factor B, albumin) was pretranslational as shown by changes in specific messenger RNA content.
Introduction
The host response to acute inflammation, the acute-phase response, is characterized by a coordinated series of metabolic reactions involving different tissues and organ systems. Fever, leukocytosis, increased muscle proteolysis, alterations in carbohydrate, lipid, and trace mineral metabolism, and profound changes in the plasma concentrations of liver-derived plasma proteins occur. When the inflammatory process is prolonged, these changes in basal metabolism may result in chronic wasting, or cachexia.
In a variety of experimental systems it has now been shown that a monokine, interleukin 1 (IL-l),I can elicit many of the metabolic reactions that constitute the acute-phase response (1, 2) . We have recently shown that this monokine mediates changes in hepatic gene expression characteristic of the acute-phase response. ILlI increased the expression of positive, acute-phase reactants, complement factor B, and the third component of complement (C3), and decreased the expression of negative acutephase reactant albumin in primary cultures ofmouse hepatocytes (3) and human hepatoma cells (4) . Furthermore, increases in expression of factor B were also elicited by IL-l in murine fibroblast cell lines transfected with cosmid DNA bearing the human second component of complement (C2) and factor B genes (4) . Cachectin/tumor necrosis factor (TNF), another cytokine released by mononuclear phagocytes in response to lipopolysaccharide, elicits a complex repertoire of metabolic reactions during inflammation (5) . This molecule was originally identified as a factor producing cachexia in experimental animals. It has since been shown to decrease the synthesis of anabolic enzymes in adipose tissue (6) (7) (8) , and recently found to be identical to tumor necrosis factor, a monokine that produces hemorrhagic necrosis oftumors (9, 10) . TNF has been cloned and its complete nucleotide sequence determined. The human TNF complementary DNA (cDNA) is 1,585 basepairs long, and encodes an -25-kD precursor and a mature protein of 17.3 kD (1 1, 12). TNF is structurally distinct but shares several functional characteristics with IL-1. It produces fever in experimental animals (13) , stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts (14) , and augments the phagocytic activities of neutrophils (15) . Moreover, IL-I has been shown to elicit effector functions that were previously associated with TNF, including tumor cytostasis (16, 17) and suppression oflipoprotein lipase activity in adipocytes (18) . Accordingly, we examined the possibility that TNF was similar to IL-l in regulation of the expression of hepatic gene products that are affected during the acute-phase response.
Methods

Materials
nidine isothiocyanate from Fluka AG, Buchs, Switzerland, and sodium N-laurylsarcosinate from ICN Pharmaceuticals, Inc., Irvine, CA. Goat anti-human factor B, goat anti-human C3, goat anti-human C4, goat anti-human albumin were purchased from Atlantic Antibodies, Scarborough, ME, rabbit anti-human a, proteinase inhibitor, rabbit antihuman a, antichymotrypsin, rabbit anti-human inter-a-trypsin inhibitor, rabbit anti-human a, acid glycoprotein, and rabbit anti-human transferrin were purchased from Dako Corp., Santa Barbara, CA, and sheep anti-human C2 came from Seward Laboratories, London, England. Recombinant-generated human TNF was kindly provided by Genentech, South San Francisco, CA, and recombinant-generated human pI 7.0 IL-1, R006B (24 kD), and R006T (17 kD) were provided by Cistron Technology (Pine Brook, NJ). These preparations contain <80 pg endotoxin/ mg protein (13) . Recombinant-generated human pI 5.0 IL-1 was purchased from Genzyme, Boston, MA, and human monocyte IL-1 was purified by previously described methods (4, 19) .
Methods
Cell culture and biosynthetic labeling. Confluent monolayers of Hep G2 and Hep 3B and murine fibroblast L cells transfected with cosmid DNA bearing the human C2 and factor B genes were maintained as previously described (20, 21) . After incubation without or with a specified monokine, monolayers were rinsed three times with HBSS, and then incubated for 30 min at 37°C in DME lacking methionine but supplemented with
[35S]methionine, 250 uCi/ml. At the end ofthis labeling interval, culture medium was discarded, monolayers rinsed several times, and cells solubilized in phosphate-buffered saline (PBS) containing 1% Triton X-100, 0.5% deoxycholic acid, 10 mM EDTA, 2 mM phenylmethylsulfonylfluoride (PMSF), 100 Lg/ml leupeptin, and pepstatin A, with two freezethaw cycles. Lysates were clarified by centrifugation at 15,000 g for 30 min and stored at -70°C. Trichloroacetic acid (TCA)-precipitable protein was determined as previously described (22) .
Immunoprecipitation and SDS-polyacrylamide gel electrophoresis (PAGE). Aliquots of cell lysate were incubated overnight at 4°C in 1% Triton X-100/1% SDS/0.5% deoxycholic acid, with excess antibody. Immune complexes were precipitated with excess formalin-fixed staphylococci-bearing protein A, washed, released by boiling in sample buffer, and applied to SDS-PAGE under reducing conditions as described by Laemmli (23 (25) .
Filters were then hybridized with [32P]labeled cDNA probes for human factor B (26), C2 (27), C3 (28) , and albumin (29) . After hybridization, filters were washed extensively, dried, and exposed to x-ray film for autoradiography.
Densitometry was conducted on the Quick Scanner (Helena Laboratories, Beaumont, TX) equipped with an integrator.
Results
TNF increases the biosynthesis of several hepatic acute-phase proteins and decreases the biosynthesis of albumin and transferrin. Human hepatoma cells (Hep G2 and Hep 3B) were incubated in medium containing TNF or IL-l for 18 h, then biosynthetically labeled for 30 min. Several secretory proteins were detected in the intracellular lysates by immunoprecipitation, SDS-PAGE, and fluorography ( Fig. 1 ). There was an increase in biosynthesis of factor B, C3, and a, antichymotrypsin and a decrease in biosynthesis of albumin and transferrin in the presence of each monokine. The addition of IL-l or TNF to hepatoma cells resulted in -2.5-3.0-fold increases in synthesis of factor B, 2.0-2.5-fold increases in C3, and 2.0-2.5-fold decreases in synthesis of albumin and transferrin (Table I) The effect of TNF on biosynthesis of hepatic secretory proteins was dose related (Fig. 2 ). An increase in synthesis of C3 A. and decrease in synthesis of albumin could be demonstrated after incubation of hepatoma cells in concentrations of TNF as low as 50 pg/ml (-3 pM; -4 X 104 molecules/cell). A similar dose-dependent increase in synthesis of factor B was observed (data not shown), but there was no change in synthesis of total TCA-precipitable protein or C2 at any concentration of TNF. Increases in the biosynthesis of C3 and factor B were not due to contamination of the TNF preparation by endotoxin, since endotoxin alone (up to concentrations of 100 ng/ml) had no effect on the synthesis ofthe complement proteins in hepatoma cells (Cole, from human monocytes (13) , it was necessary to examine the possibility that changes in hepatic protein synthesis mediated by TNF involved induction ofIL-l expression in hepatoma cells. Human hepatoma cells (Hep G2 and Hep 3B) were incubated in control medium or medium supplemented with TNF (100 ng/ml) for intervals of 6-12 h followed by isolation of total cellular RNA. This RNA was then subjected to RNA blot analysis using human IL-l cDNA (32) as probe and human monocyte RNA as positive control. A 1.7 kilobase (kb) mRNA was present in human monocytes but not in human hepatoma cells (data not shown). There was no evidence ofIL-1 mRNA in hepatoma cells incubated with lipopolysaccharide (1 ,Ag/ml). Finally, there was no evidence for synthesis of TNF in hepatoma cells incubated in control medium or medium supplemented with IL-I or TNF (data not shown).
TNF also mediated a dose-ependent increase in biosynthesis of factor B in a stable transfected cell line (21) of mouse L cells transfected with cosmid DNA bearing the human C2 and factor B genes (Fig. 3) . At a concentration of 100 ng/ml of TNF or IL-1, the increase in factor B synthesis was similar. The effect of TNF on the expression of factor B after DNA-mediated gene transfer was highly selective, in that there was no change in the expression of the contiguous C2 gene in the transfected L cells. Biosynthesis of endogenous C3 in murine L cells also increased in the presence of TNF (data not shown). Endogenous synthesis of factor B was not detected in parent untransfected LtK mouse L cells incubated in medium supplemented with TNF (data not shown) or IL-1 (4). There was no effect on cell number, viability, or total TCA-precipitable protein synthesis in this cell line up to TNF concentrations of 300 ng/ml, which indicated that the LtK-mutants ofthe mouse L cell lineage are relatively resistant to the cytotoxic effects of TNF.
Regulation of hepatic acute-phase gene expression by TNF is pretranslationaL Total cellular RNA was isolated from hepatoma cells that had been incubated with IL-I or TNF for 12 h and then subjected to RNA blot analysis. TNF mediated an increase in factor B mRNA concentration and a decrease in albumin messenger RNA (mRNA) concentration (Fig. 4) . At a concentration of 100 ng/ml TNF or IL-1 the changes in specific mRNA levels were similar. There was also an increase in C3 mRNA concentration, but C2 and C4 mRNA concentrations were not affected by TNF or IL-1. Changes in steady state levels of factor B, C3, and albumin mRNA were also dose dependent (data not shown). Regulation of hepatic gene expression by TNF is time dependent and reversible. Monolayers of hepatoma cells were incubated with TNF or IL-I for several time intervals up to 24 h. Total cellular RNA was isolated for RNA blot analysis, and biosynthetic labeling was done in parallel experiments. Factor B mRNA concentration increased between 1 and 3 h of incubation in IL-I or TNF (Fig. 5) . There was an unexpected decrease in factor B mRNA concentration after 1 h incubation in TNF on two separate blots. There was no decrease in ethidium bromide-stained 28 S and 18 S RNA or in C2 mRNA at that time on either blot. This may mean that there is an initial decrease in factor B mRNA in the presence of TNF, but by 3 h of incubation factor B mRNA concentration consistently increases and later reaches a steady-state level comparable with that in IL-i-supplemented medium. There was not a corresponding decrease in the rate of synthesis of factor B during the shortest interval ofincubation in TNF-supplemental medium (3 h increase in synthesis offactor B protein and decrease in synthesis ofalbumin were detected between 3 and 6 h ofincubation (data not shown).
Mr
Regulation of factor B and albumin expression by TNF was also reversible. Monolayers of hepatoma cells that had been incubated with TNF for 6 h were rinsed and incubated without TNF for a series of time intervals up to 24 h. Cells were then radiolabeled. Biosynthesis offactor B decreased to baseline within 3-6 h, but synthesis ofalbumin did not increase to baseline until 12-24 h (data not shown).
Hepatic acute-phase gene expression is mediated by TNF and multipleforms ofIL-I. Changes in expression of factor B, C3, and albumin mediated by recombinant-generated human TNF were compared to those mediated by recombinant-generated human pl 7.0 IL-1 precursor (24 kD), recombinant-generated human pI 7.0 IL-I (17 kD), recombinant-generated human pI 5.0 IL-1, and purified human monocyte pI 7.0 IL-I (Fig.  6) . Biosynthesis of C3 increased and synthesis of albumin decreased in each case. The magnitude ofthe changes in synthesis of C3 and albumin were less in the case of pI 7.0 IL-I (17 kD) and pH 5.0 IL-1. These differences in dose response could result from differences in method of isolation, relative stability of the precursor and mature forms ofIL-I in cell culture fluid, or from primary structural differences between pI 5.0 and pI 7.0 IL-1 polypeptides (33).
Discussion
TNF is a monokine that directly affects the functional state of several different tissues. It produces hemorrhagic necrosis oftumors in animals (5), suppresses lipid biosynthesis in adipose tissue (6) (7) (8) , modulates proteolytic activity in connective tissue (14) , augments granulocyte phagocytic activity (15) , regulates the expression of histocompatibility antigens (34) and inter-a-trypsin inhibitor) and negative (albumin, transferrin) directions. In addition to differences in primary structure, TNF and IL-1 are recognized by distinct cell surface receptors in at least one cell type that has been examined, namely cultured adipocytes (18) . If these two molecules are also recognized by different receptors on the surface of hepatocytes it would mean that regulation of several discrete genes in a similar fashion is elicited by two different signal recognition systems. Transduction ofa common second signal, or triggering of a common transcriptional or posttranscriptional processing mechanism by different second messengers, could explain these observations. Several characteristics ofTNF suggest that in vivo it may be an important, if not dominant, mediator of the hepatic acutephase response. First, radiolabeled TNF is concentrated in the liver after intravenous administration (35) . Second, TNF may be released in higher concentrations than IL-I under certain circumstances; e.g., rabbits injected with endotoxin (35) . Third, TNF mediates changes in hepatic gene expression in hepatoma cells that appear to express only small numbers ofTNF receptors (36) . An increase in TNF receptor number resulting from the action of other mediators released during acute inflammation may further augment the hepatic effects of TNF. Interferon-y, for example, increases TNF receptor number two to threefold in a cervical carcinoma cell line (37) . Finally, the effect of TNF in vivo may be amplified by autocrine, or paracrine, stimulation of IL-I release (13) .
The mechanism of regulation of hepatic acute-phase gene expression by TNF and IL-l is likely to be transcriptional. Changes in specific mRNA concentrations presented here represent steady state levels, or the balance between transcription and mRNA turnover. However, Kulkarni et al. have shown that changes in the expression of al acid glycoprotein and albumin in rat liver after subcutaneous turpentine injection primarily reflect changes in rate of transcription (38) . Further studies will be necessary to prove that transcriptional regulation is elicited by highly purified monokines, IL-I and TNF, and to determine whether the same mechanism can be implicated in their effects on different hepatic gene products. Plasma concentrations ofC4 and a, proteinase inhibitor increase during acute inflammation but synthesis of these hepatic secretory proteins in human hepatoma cells is not affected by IL-I or TNF. It is possible that posttranslational processing, secretion, and/or extracellular turnover are important levels of control for these and other hepatic secretory proteins during acute inflammation.
These experiments indicate that hepatic acute-phase gene expression can result from the direct action of two distinct monokines, but do not exclude the possibility that other mediators are involved. A hepatocyte-stimulating factor, which appears to be distinct from IL-1 (39) , and lymphotoxin, which shares >40% homology with TNF (12) and occupies the same receptor as TNF (36) , are likely candidates.
